Preview Newsletter
XARELTO Media Monitoring Week of 2/27/15
-
National Lawsuits Filed On Behalf Of Xarelto Users Injured By Drug
Feb 26, 2015 | PR News Wire
By The Cochran Firm
Lawsuits filed by the COCHRAN FIRM against the makers of Xarelto allege the drug - a blood thinner used to prevent strokes and other injuries associated with clotting disorders - has resulted in numerous serious injuries and death resulting from uncontrollable bleeding. Recent filings on behalf of the Firm's clients in Tennessee, North Carolina, Georgia, Alabama and Floridahave been transferred to the Federal Court Eastern District of Louisiana. MDL number 2592. -
Federal Xarelto Lawsuits Progress, As Bernstein Liebhard LLP Comments on Issuance of Most Recent Pretrial Order
Feb 26, 2015 | PR Web
By Bernstein Liebhard LLP
The federal litigation established for Xarelto lawsuits (http://www.xareltolawsuit2015.com/) continues to move forward in the U.S. District Court, Eastern District of Louisiana, Bernstein Liebhard LLP reports. According to court records, the proceeding issued its eighth Pretrial Order on February 13, 2014. (In Re: Xarelto Products Liability Litigation, No. 2592) -
Xarelto Status Conference this Week
Feb 26, 2015 | PR Web
By Onder, Shelton, O'Leary & Peterson, LLC
Attorneys handling Xarelto lawsuit claims report an anticipated Status Conference in the Xarelto Products Liability Litigation multidistrict litigation (MDL 2592) now underway in Louisiana District Court. The status conference is scheduled to take place this Friday, February 27 at 9:00 am, according to court documents. -
Xarelto Lawsuit News: Bayer and Johnson & Johnson Pursue Additional FDA Approvals for Xarelto while Cases against the Blood Thinner are Consolidated into Multidistrict Litigation
Feb 25, 2015 | PR News Wire
By MT Services LLC
MT Services LLC, a Lawsuit Settlement News Reporting Company which operates lawsuitsettlementnews.com, announced today that a recent announcement by Bayer and Johnson & Johnson was made stating that they will pursue additional FDA approvals for Xarelto, their blood thinner drug, despite the fact that lawsuits against them have been consolidated into multidistrict litigation in two U.S. courts. According to Drug Watch, the announcement was made last month by Bayer and J&J, and they seek further federal approvals for Xarelto for stroke patients. -
Xarelto Caused Dangerous Internal Bleeding, Plaintiff Alleges
Feb 27, 2015 | Top Class Actions
By Laura Schultz
A new Xarelto lawsuit has been filed by Kenneth S. in a Pennsylvania federal court against Janssen Research & Development, Johnson & Johnson, and Bayer Corporation. Kenneth is seeking damages for injuries he allegedly incurred while taking Xarelto. -
Study Unveils Xarelto Clinical Trial Misconduct
Feb 26, 2015 | Injury Lawyer
By Laura Woods
Xarelto bleeding complications may have been falsified, according to a recent report on clinical trial misconduct. The report suggests major issues with one early study on the drug, including signs that data regarding the safety of the anticoagulant may have been falsified and subsequently destroyed. -
Xarelto Bleeding Lawsuit Filed in Pennsylvania
Feb 25, 2015 | Top Class Actions
By Meredith Friesen
A Xarelto lawsuit was filed in Pennsylvania claiming Janssen Pharmaceuticals’ blood thinning drug caused the plaintiff to suffer from severe Xarelto bleeding side effects. Plaintiff Rufus H. began using Xarelto in June 2012 to treat atrial fibrillation. However, he later suffered severe gastrointestinal bleeding. Both gastrointestinal bleeding and pulmonary bleeding side effects have been associated with Xarelto. -
Xarelto, The Unstoppable Blood Thinner
Feb 24, 2015 | Pogust Braslow & Millrood
If you’ve ever had surgery — say, a knee replacement — or a diagnostic procedure like a heart catheterization, it’s very likely you were given an anticoagulant drug to prevent blood clots. Older patients are often on a regular anticoagulant regimen to prevent strokes and treat atrial fibrillation (irregular heartbeat). -
Son Files Xarelto Lawsuit over Mother’s Bleeding Death
Feb 23, 2015 | Top Class Actions
By Amanda Antell
Alabama plaintiff Timothy W. is suing Janssen and Bayer Pharmaceuticals for the wrongful death of his mother, Thelma B., which he alleges was caused by Xarelto bleeding complications. -
Xarelto bleeding lawsuits on the rise
Feb 23, 2015 | Hissey Kientz LLP
Xarelto bleeding lawsuits are on the rise as more patients come forward with complaints of side effects after using the blood-thinning drug. A West Virginia woman who suffered a gastrointestinal bleed after being prescribed Xarelto to treat atrial fibrillation is the most recent patient to file a Xarelto lawsuit. -
Xarelto Lawsuit Claims In Pennsylvania Consolidated In A Mass Tort Program In Philadelphia State Court
Feb 20, 2015 | Oliver Law Group PC
he Xarelto attorneys at The Oliver Law Group P.C. report that all Xarelto bleeding lawsuits filed in Pennsylvania have been consolidated in the Philadelphia Court of Common Pleas. Common Pleas Administrative Judge Kevin Dougherty issued an order on January 20 2015 to create a mass tort litigation for the Xarelto complaints filed against Bayer Healthcare Pharmaceuticals, which manufacturers Xarelto, and Johnson & Johnson’s subsidiary, Janssen Pharmaceuticals, which markets Xarelto. In consolidating the Xarelto lawsuits, Judge Dougherty granted a petition from plaintiffs in Xarelto cases who asked for the consolidation due to the lawsuits having common allegations that Xarelto can cause severe and uncontrollable bleeding that can sometimes be fatal.
Client Attorney Privileged/Attorney Work Product/At Request of Counsel
Plaintiff Attorney Press Releases
Plaintiff Attorney Blogs
Full Text of Stories Below
-
National Lawsuits Filed On Behalf Of Xarelto Users Injured By Drug
Feb 26, 2015 | PR News Wire
By The Cochran Firm
Lawsuits filed by the COCHRAN FIRM against the makers of Xarelto allege the drug - a blood thinner used to prevent strokes and other injuries associated with clotting disorders - has resulted in numerous serious injuries and death resulting from uncontrollable bleeding. Recent filings on behalf of the Firm's clients in Tennessee, North Carolina, Georgia, Alabama and Floridahave been transferred to the Federal Court Eastern District of Louisiana. MDL number 2592.
MARKETED AS BEING SAFE AND EFFECTIVE
The complaints filed on behalf of our clients further allege that Xarelto was marketed as being safe and effective, with no need for inconvenient monitoring and with convenient once a day dosing. However, when used in this fashion, the complaints allege that the drug is linked to an increased risk of gastrointestinal bleeding and other serious bleeding events, some of which have been fatal.
The complaints filed by the COCHRAN FIRM all share the same allegations, that the drug manufacturers failed to warn about the potential for severe adverse effects from taking Xarelto, especially an increased risk associated with the once a day dosing and the claim that the drug blood levels need not be monitored. The claims filed allege that uncontrollable bleeding has caused their clients to endure hospitalizations, blood transfusions and in severe cases death.
CLAIMANTS ALLEGE THERE IS NO ANTIDOTE TO REVERSE THE BLEEDING SIDE EFFECTS CAUSED BY XARELTO
The plaintiffs allege that there is no approved antidote available for patients using Xarelto, and many of the bleeding events have resulted in catastrophic outcomes where doctors were unable to control the bleeds.
CLAIMANTS ALLEGE THAT INJURIES AND DEATHS WERE AVOIDABLE
According to the claims, severe injuries and deaths were avoidable if the pharmaceutical companies had not provided misleading information about the blood monitoring and dosing, and if stronger warnings had been provided about a lack of a Xarelto reversal agent or antidote.
ABOUT THE COCHRAN FIRM
The Cochran Firm has 25 offices across the United States and is seeking compensation for all those suffering injuries after taking Xarelto. The Cochran Firm offers free and confidential consultations for people seeking representation for harm to themselves or a loved one caused by Xarelto. Those who are interested in exploring their legal rights in regards to Xarelto injuries may contact The Cochran Firm athttp://cochranfirmdothan.com/xarelto-risks-bleeding or call 1-800-LAW-HELP.
-
Feb 26, 2015 | PR Web
By Bernstein Liebhard LLP
The federal litigation established for Xarelto lawsuits (http://www.xareltolawsuit2015.com/) continues to move forward in the U.S. District Court, Eastern District of Louisiana, Bernstein Liebhard LLP reports. According to court records, the proceeding issued its eighth Pretrial Order on February 13, 2014. (In Re: Xarelto Products Liability Litigation, No. 2592)
“The Order indicates that the Court has established standards and procedures pertaining to the litigation’s Common Benefit Fund, which will apply to any attorney representing a Xarelto plaintiff in the Eastern District of Louisiana, as well as any who represent such a plaintiff in state court who benefits from work performed in the federal multidistrict litigation,” says Bernstein Liebhard LLP, a nationwide law firm representing the victims of defective drugs and medical devices. The Firm is currently representing numerous plaintiffs who have Xarelto lawsuits pending in the federal proceeding, and continues to offer free, no-obligation legal reviews to individuals who allegedly suffered serious injuries from the blood thinner, including uncontrollable bleeding, strokes, deep vein thrombosis or pulmonary embolism.
Xarelto Litigation
According to court records,the federal Xarelto litigation was established by an Order of the U.S. Judicial Panel on Multidistrict Litigation in December 2014. Initially, just 21 actions filed on behalf of individuals who allegedly experienced uncontrollable internal bleeding and other complications due to their use of Xarelto were transferred to the proceeding. Court documents now indicate that at least 220 claims had been filed in the proceeding as of February 17, 2015. According to Bernstein Liebhard LLP, multidistrict litigations, such as the one established for Xarelto lawsuits, are created to allow a large number of cases involving common questions of fact to undergo coordinated pretrial proceedings. This allows the lawsuits to move more efficiently through the court system by avoiding duplicative discovery and inconsistent court rulings across the docket. All federally-filed claims involving the blood thinner are now subject to transfer to the consolidated proceeding.All of the Xarelto lawsuits pending in the Eastern District of Louisiana similarly allege that use of the blood thinning medication caused patients to experience life-threatening complications, including uncontrollable bleeding, hemorrhagic strokes, deep vein thrombosis and pulmonary embolism. Among other things, plaintiffs charge that the manufacturers of the drug downplayed the risk of serious bleeding in promotional materials for Xarelto, and wrongly positioned it as a superior alternative to warfarin, a blood thinner that has been in use for decades. The lawsuits point out that while hemorrhaging associated with warfarin can be stopped via the administration of vitamin K, there is currently no approved antidote to reverse Xarelto bleeding.
Xarelto patients who allegedly experienced life-threatening episodes of internal bleeding and other complications related to its use may be entitled to compensation for medical bills, lost wages, pain and suffering and more. Learn more about filing a Xarelto lawsuit by visiting Bernstein Liebhard LLP’s website, or by calling 800-511-5092 to schedule a free, no obligation case review.
About Bernstein Liebhard LLP
Bernstein Liebhard LLP is a New York-based law firm exclusively representing injured persons in complex individual and class action lawsuits nationwide since 1993. As a national law firm, Bernstein Liebhard LLP possesses all of the legal and financial resources required to successfully challenge billion dollar pharmaceutical and medical device companies. As a result, our attorneys and legal staff have been able to recover more than $3 billion on behalf of our clients. The Firm has been named by The National Law Journal to the Plaintiffs’ Hot List, recognizing the top plaintiffs firms in the country, for the past 12 consecutive years. Bernstein Liebhard LLP is the only firm in the country to be named to this prestigious list every year since it was first published in 2003. -
Xarelto Status Conference this Week
Feb 26, 2015 | PR Web
By Onder, Shelton, O'Leary & Peterson, LLC
Attorneys handling Xarelto lawsuit claims report an anticipated Status Conference in the Xarelto Products Liability Litigation multidistrict litigation (MDL 2592) now underway in Louisiana District Court. The status conference is scheduled to take place this Friday, February 27 at 9:00 am, according to court documents.
Xarelto lawsuits were first consolidated in Louisiana in December of 2014. Plaintiffs involved in the litigation allege that they have suffered injuries as a result of Xarelto, including but not limited to internal bleeding, stroke, deep vein thrombosis, and pulmonary embolism. Among the counts plaintiffs have filed against drug’s makers, Bayer and Johnson and Johnson, are allegations that the drug’s warning label did not adequately caution consumers serious health risks associated with the drug. Furthermore, plaintiffs claim Xarelto was promoted as superior to warfarin, which they assert is false.
To date, nearly 100 claims have been filed as part of the consolidated Xarelto lawsuits, according to court documents. These claims share common facts, each having been filed by or on behalf of a person who suffered from internal bleeding or stroke they say are connected to Xarelto.
Early status conferences establish methods and procedures for pretrial proceedings such as the Discovery process, according to the Onder Law Firm. As Xarelto lawsuits progress, new claims may be consolidated at any time. Lawyers handling national Xarelto lawsuits are accepting inquiries from persons and the families of persons who suffered an injury while taking Xarelto. These inquiries will be considered for possible inclusion in the multidistrict litigation. Distinct from class action lawsuits, MDLs enable an efficient processing of similar claims, such as in the case of a defective or dangerous product, while preserving the individual details of each case for trial or settlement purposes, according to attorneys handling Xarelto claims at the Xarelto Contingency Lawsuit website.
The Onder Law Firm is renowned for its achievements in product and consumer safety litigation, with a strong track record of winning meaningful settlements for clients. The firm is nationally-renowned for its work on window blind strangulation, and has notable expertise in fighting on behalf of individuals against powerful corporations. Individuals and the family members of individuals who have suffered from internal bleeding and have taken Xarelto are eligible for a no-cost, no-obligation Xarelto lawsuit case review, and may contact the firm through its Xarelto Contingency Lawsuit website. The firm provides information on bleeding warnings and Xarelto lawsuit news.
The Onder Law Firm also welcomes Xarelto lawsuit inquiries from other law firms, either to handle these inquiries or work as co-counsel.
About The Onder Law Firm
Onder, Shelton, O'Leary & Peterson, LLC is a St. Louis based personal injury law firm handling serious injury and death claims across the country. Its mission is the pursuit of justice, no matter how complex the case or strenuous the effort. Onder, Shelton, O'Leary & Peterson has represented clients throughout the United States, and other firms throughout the nation often seek its experience and expertise on complex litigation. It is a recognized leader in products liability cases such as window blind cord strangulation and pharmaceutical litigation. The Onder Law Firm’s Xarelto attorneys provide information to the public and free, confidential case evaluation athttp://www.XareltoContingencyLawsuit.com. -
Feb 25, 2015 | PR News Wire
By MT Services LLC
MT Services LLC, a Lawsuit Settlement News Reporting Company which operates lawsuitsettlementnews.com, announced today that a recent announcement by Bayer and Johnson & Johnson was made stating that they will pursue additional FDA approvals for Xarelto, their blood thinner drug, despite the fact that lawsuits against them have been consolidated into multidistrict litigation in two U.S. courts. According to Drug Watch, the announcement was made last month by Bayer and J&J, and they seek further federal approvals for Xarelto for stroke patients.
The public announcement was made amidst the news that plaintiffs have continued to file lawsuits over the companies, and in December and January, judges both in Pennsylvania and Louisiana consolidated cases into multidistrict litigation (MDL) as well as a mass tort program. Over 100 filed lawsuits, with claims of serious health problems and even death as a result of using Xarelto, are now awaiting trial.
Chris Janish, CEO of MTS commented on the recent news regarding Bayer and Johnson & Johnson, "The recent FDA request is one that will be watched carefully by legal experts, especially in light of the fact that Xarelto lawsuit filings continue to rise each month. The blood thinner drug has showed promising results, however, the lawsuit claims being filed will determine at what cost. What the FDA has to say about the new approval request may determine an important direction in the Xarelto mass tort litigation."
MTS is ready and able to assist those who need lawsuit help with finding a qualified Xarelto law firm or Xarelto lawyer to provide a free evaluation on their specific case. To learn more about MTS' services involving Xarelto, Pradaxa, or other blood thinner litigations, please visit:http://www.lawsuitsettlementnews.com/pradaxa-all-blood-thinner-cases
If you already have an attorney and have filed a lawsuit and need a lawsuit funding cash advance, not to be confused with a lawsuit loan or pre-settlement loan, Lawsuit Settlement News can assist you with these services. Injured parties from Pradaxa or Xarelto usage and complications can apply for up to $50K in pre-settlement or settlement lawsuit funding. For a full list of the services that the company provides, visit:http://www.lawsuitsettlementnews.com/about-our-products-and-services
If you, or a loved one, have been injured by Xarelto or Pradaxa and need lawsuit money or lawsuit help, including finding a Xarelto or Pradaxa law firm, call 877.571.0405 to speak with an available agent. You may also fill out a quick application online at: www.lawsuitsettlementnews.com and an agent will contact you shortly.
Disclaimer: MT Services LLC, operator of Lawsuitsettlementnews.com, is not a law firm and cannot provide legal advice on your case; however, MTS works with lawyers involved in mass tort litigations who are willing to provide a free legal consultation at the consumer's request. For a list of full disclosures please visit the company's website disclosure page at:http://www.lawsuitsettlementnews.com/terms-of-service
-
Xarelto Caused Dangerous Internal Bleeding, Plaintiff Alleges
Feb 27, 2015 | Top Class Actions
By Laura Schultz
A new Xarelto lawsuit has been filed by Kenneth S. in a Pennsylvania federal court against Janssen Research & Development, Johnson & Johnson, and Bayer Corporation. Kenneth is seeking damages for injuries he allegedly incurred while taking Xarelto.
Kenneth began taking Xarelto on July 1, 2014. His doctor prescribed him the drug to reduce his chance of stroke due to atrial fibrillation, a type of heart arrhythmia. On Aug. 8, 2014, Kenneth reportedly began to suffer from internal and rectal bleeding; he was hospitalized that same day.
Kenneth remained in the hospital for nearly two weeks and had to receive nine units of blood. Due to the ensuing complications, Kenneth can no longer take blood thinners. The Xarelto lawsuit alleges that had Kenneth been properly informed of the risks associated with using Xarelto, he would have chosen a safer alternative.
The Xarelto lawsuit claims that the defendants misinformed the medical community and the general public about the effectiveness of Xarelto and ignored patient safety in their marketing process.
The Xarelto Lawsuit is Case No. 2:15-cv-00119-EEF-MBN, in the U.S. District Court for the Eastern District of Pennsylvania.Overview of Xarelto Lawsuits
Xarelto is an anticoagulant, or blood thinning medicine, prescribed to keep blood clots from forming. Xarelto was approved by the FDA in 2011 to reduce risk of blood clots, deep vein thrombosis, and pulmonary embolisms in patients who have undergone knee and hip replacement surgery. Over the next few years, the FDA approved Xarelto for reducing risk of stroke for patients with non-valvular atrial fibrillation and for long-term treatment of patients with deep vein thrombosis and pulmonary embolism.
The pharmaceutical companies marketing Xarelto claimed that this new anticoagulant is the first and only once-a-day prescription blood thinner that exists for patients without regular blood monitoring. Marketers also claimed that Xarelto, unlike its competitor warfarin, requires no dietary restrictions for its users. According to the Xarelto lawsuit, the drug has been prescribed to over 7 million people across the globe.
Xarelto manufacturers aggressively marketed the drug, resulting in large profits for the defendants. A one-year prescription of Xarelto costs patients approximately $3,000, compared to the generic form of warfarin which is about $300. Based on a World Preview report, Xarelto is estimated to be the 19th best selling drug by the year 2018. Xarelto manufacturers have been warned by the FDA that their advertising is misleading and minimizes the risks associated with taking the anticoagulant.
The side effects associated with taking Xarelto include hemorrhage and potentially serious blood clot related injuries in short term users. Surprisingly, blood clot injuries are the exact condition that Xarelto is meant to prevent. Unlike warfarin, Xarelto has no known antidote to stop uncontrolled bleeding.
Lawsuits against Xarelto are being filed by patients who have allegedly suffered serious Xarelto side effects and family members who may have lost loved ones due to the drug. Many of the Xarelto lawsuits include claims of negligence, fraud and deceit, breach of contract, and products liability. These lawsuits may help patients receive compensation for their medical bills and their pain and suffering allegedly caused by using Xarelto.
-
Study Unveils Xarelto Clinical Trial Misconduct
Feb 26, 2015 | Injury Lawyer
By Laura Woods
Xarelto bleeding complications may have been falsified, according to a recent report on clinical trial misconduct. The report suggests major issues with one early study on the drug, including signs that data regarding the safety of the anticoagulant may have been falsified and subsequently destroyed.
In early February, Jama Internal Medicine published a report by Charles Seife, of the Arthur L. Carter Institute of Journalism at New York University, revealing that the FDA frequently uncovers clinical trial misconduct and discrepancies in studies conducted by drug makers. However, this information is rarely reported to medical journals who publish the research.
Consequently, the studies are published in the medical journals, without any indication that the FDA found issues such as falsified data, unsafe practices and a complete disregard for scientific protocols. These instances are typically referred to as Official Action Indicated (OAI).
Throughout the course of his research, Seife found that most FDA clinical trial inspection records were filled with blacked out sections removing the name of the drugs, companies and researchers, making it difficult to see which clinical trials had major problems — with the exception of Xarelto.RECORD 4 rebuked by FDA
According to the report, one of the Xarelto study reports — RECORD 4 — was conducted so poorly that the FDA rejected it entirely when deciding whether or not to approve the next-generation anticoagulant. However, the report was still published in The Lancet in May 2009. While the publication of the study states that Xarelto is safe and effective for the prevention of deep vein thrombosis and pulmonary embolism after knee replacement surgery, it fails to reveal the FDA knew researchers falsified some of the data and destroyed medical records, which was presumably done to cover up questionable practices.
In 2011, Xarelto received FDA approval for the prevention of strokes among patients with atrial fibrillation. The indication was later expanded to include the prevention of deep vein thrombosis and pulmonary embolism after knee and hip surgery, which is exactly what the four RECORD trials aimed to achieve.
“Eight of 16 FDA inspections of sites involved in a clinical trial of rivaroxaban, a novel anticoagulant, had been rated OAI. These inspections had uncovered evidence of various transgressions, such as ‘systemic discarding of medical records,’ unauthorized unblinding, falsification, and ‘concerns regarding improprieties in randomization’,” Seife wrote.
“Consequently, the entire study, RECORD 4 (Regulation of Coagulation in Orthopedic Surgery to Prevent Deep-Venous Thrombosis and Pulmonary Embolism 4), was deemed unreliably by the FDA. These problems are not mentioned in the article describing the study’s results or in other publications associated with the trial.”Xarelto bleeding complications
In 2011, the FDA refused to use the information contained in RECORD 4, claiming the data integrity was so poor it could not be considered in Xarelto’s approval process. The Agency noted that inspections at five clinical trial sites revealed that researchers did not report adverse effects experienced by patients, didn’t maintain adequate medical records, failed to acquire proper consent from subjects and didn’t report unanticipated risks to human test subjects.
“Inspection of Bayer Pharmaceuticals as the sponsor of the four RECORD 4 studies revealed that the sponsor failed to 1) ensure proper monitoring of the study, 2) ensure the study was conducted in accordance with the protocol and/or investigational plan, and 3) to ensure that FDA and all investigators were promptly informed of significant new adverse effects or risks,” FDA reviewers determined.
In addition to the unreliable data found in RECORD 4, the FDA also found issues with RECORD 2 and RECORD 3. The Xarelto website also sites only RECORDS 1-3, also eliminating the use of RECORD 4.
The findings come on the heels of mounting lawsuits involving uncontrolled Xarelto internal bleeding, for which there is no antidote. Plaintiffs claim that Xarelto manufacturers downplayed this major risk in an effort to boost sales.
-
Xarelto Bleeding Lawsuit Filed in Pennsylvania
Feb 25, 2015 | Top Class Actions
By Meredith Friesen
A Xarelto lawsuit was filed in Pennsylvania claiming Janssen Pharmaceuticals’ blood thinning drug caused the plaintiff to suffer from severe Xarelto bleeding side effects.
Plaintiff Rufus H. began using Xarelto in June 2012 to treat atrial fibrillation. However, he later suffered severe gastrointestinal bleeding. Both gastrointestinal bleeding and pulmonary bleeding side effects have been associated with Xarelto.
Rufus was hospitalized in February 2014 to treat the alleged Xarelto bleeding. He alleges that had he been fully aware of the possibility of severe Xarelto bleeding, he would never have used the medication, according to the Xarelto lawsuit.
Furthermore, the Xarelto bleeding lawsuit states that there was no way that the treating physicians could have been aware of the high risks associated with Xarelto use.Xarelto Bleeding Side Effects
The defendants have been persistent in their support of Xarelto stating that “Xarelto has been proven to lower the chance of having a stroke if you have atrial fibrillation” and that the drug “begins working a few hours after you start taking it, and keeps working for as long as you take it,” according to the Xarelto lawsuit.
One of the driving points for Xarelto promotion has been that Xarelto does not need “regular blood monitoring and there are no dietary restrictions.” This sets Xarelto apart from warfarin, the go-to anticoagulant for decades.
However, many patients have suffered from severe Xarelto bleeding side effects after using the drug. Pulmonary bleeding and gastrointestinal bleeding side effects are always a risk with anticoagulant drugs. However, warfarin has an antidote should severe internal bleeding occur. Xarelto has no such remedy. Many patients have died from Xarelto bleeding side effects.
The Xarelto bleeding lawsuit states: “Defendants have created a new drug, Xarelto, that is not better than warfarin from a safety perspective, and at best, is only perhaps slightly easier to use and administer.”
The Xarelto lawsuit accuses Janssen of failing to warn patients about the risk of Xarelto bleeding as well as the fact that there is no antidote. The Xarelto lawsuit alleges that “the current warning is simply inadequate. The Defendants have failed and continue to fail in their duties to warn and protect the consuming public, including the Plaintiff.”
Xarelto belongs to a class of anticoagulants called Factor Xa. All other medications in this class have been associated with severe internal bleeding side effects. Many drug manufacturers have faced lawsuits accusing them of failing to warn and creating a defective drug. Wrongful death lawsuits have also been filed.
A Xarelto class action lawsuit investigation is currently underway.
This Xarelto Lawsuit is Case No. 2:14-cv-00118 filed in the U.S. District Court for the Eastern District of Pennsylvania.
-
Xarelto, The Unstoppable Blood Thinner
Feb 24, 2015 | Pogust Braslow & Millrood
If you’ve ever had surgery — say, a knee replacement — or a diagnostic procedure like a heart catheterization, it’s very likely you were given an anticoagulant drug to prevent blood clots. Older patients are often on a regular anticoagulant regimen to prevent strokes and treat atrial fibrillation (irregular heartbeat).
For years, Coumadin (warfarin) was the “go-to” anti-clotting drug. But it must be carefully monitored and the dosage raised or lowered in response to the individual’s changing needs. For this reason, when Bayer came out with Xarelto (rivaroxaban) in 2011, it was welcomed as a drug that would treat clotting tendency while offering simplicity in prescribing and ingesting. No weekly or monthly blood tests. No dietary changes.What more could you want? Maybe an antidote.
Occasionally people who are taking a blood thinner experience an episode of bleeding — perhaps from an injury, an ulcer, or if surgery is required. The anticoagulant effect of Coumadin can be reversed by the administration of Vitamin K. Patients who have been taking Xarelto, however, are at risk of an uncontrollable bleed because there is no known antidote to the drug — something the manufacturers didn’t talk about.
Xarelto has been reported to have caused irreversible internal bleeding in the brain, the eye, the stomach, and intestines. Older patients are at an even higher risk of serious bleeding, including lethal bleeds, because of their balance and trip and fall issues; the bruising or cuts resulting from a fall are potentially much more dangerous for elderly persons taking the blood thinner Xarelto. It has also been found that those who routinely take NSAIDS (such as aspirin, Motrin or Advil) for arthritis pain are more than twice as likely to have a major bleed if they also take Xarelto.
Thousands of reports of adverse events connected to Xarelto have been filed the world over — in Germany, Ireland, Canada — and in the U.S. between 2011 when Xarelto hit the market and 2013, more than 700 such reports had been filed.
Many Xarelto victims are seeking redress in the courts — so many, in fact, that they are being consolidated into mass torts so they can be handled more efficiently. Xarelto claims which have been (and continue to be) filed in federal courts across the country are being coordinated by a federal district in Louisiana. These plaintiffs, scattered from Florida to Utah to New York, all allege that they “suffered severe bleeding or other injuries as a result of taking Xarelto (rivaroxaban) and that the defendants did not adequately warn prescribing physicians or consumers of the risks associated with Xarelto, including the potential for severe or fatal bleeding and the unavailability of a reversal agent to counteract Xarelto’s anticoagulation effects. Issues concerning the development, manufacture, regulatory approval, labeling, and marketing of Xarelto thus are common to all actions.”
So many Xarelto cases have been filed in Pennsylvania state courts that the Philadelphia County Court of Common Pleas created a mass tort program (MTP) in January 2015 to consolidate them for judicial economy. These claims also have common issues about Bayer and Johnson & Johnson’s failure to provide adequate warnings of the risk of uncontrollable bleeding and the lack of an effective antidote.Has someone in your family been harmed by Xarelto?
Pogust Braslow & Millrood is currently investigating claims of uncontrollable bleeding caused by Xarelto. If you have incurred medical expenses and lost income because of an episode of internal bleeding related to your use of Xarelto, or if your loved one died because Xarelto caused them to experience an irreversible and fatal bleeding event, we can help.
For more information about this topic or to schedule a free consultation about your Xarelto claim, contact the Pennsylvania Xarelto litigation team at Pogust Braslow & Millrood online or call 1-888-348-6787.
-
Son Files Xarelto Lawsuit over Mother’s Bleeding Death
Feb 23, 2015 | Top Class Actions
By Amanda Antell
Alabama plaintiff Timothy W. is suing Janssen and Bayer Pharmaceuticals for the wrongful death of his mother, Thelma B., which he alleges was caused by Xarelto bleeding complications.
Timothy claims in the Xarelto lawsuit that his mother died as a direct result of the drug’s design defects and lack of bleeding antidote, and that Xarelto manufacturers withheld this information to preserve the product’s market value.
Timothy’s mother was prescribed Xarelto in early December 2012 and passed away shortly after on Dec. 19, 2012. According to the Xarelto lawsuit, Thelma developed Xarelto internal bleeding injuries and later died from this event. Due to the lack of a Xarelto bleeding antidote, she could not be saved despite hospital intervention and other medical care.
Like many patients across the country, Timothy’s mother had been prescribed Xarelto to prevent stroke. Xarelto had proven to be a successful blood-thinner, so much that it had become the most popular anticoagulant soon after its release in 2011. Unfortunately, many patients discovered a fatal internal bleeding Xarelto side effect when using the drug.
After discovering that Xarelto lacked a bleeding antidote, Timothy filed a wrongful death Xarelto lawsuit. In his lawsuit, he claims that Xarelto is an unreasonably dangerous drug that was unsafe for his mother as well as other patients to use. Furthermore, Bayer and Janssen should have taken stronger precautionary measures against this Xarelto complication, and should have warned their consumers that there was no bleeding antidote despite the risk, he contends.
The plaintiff’s lawyers state that Janssen and Bayer had the civil responsibility to warn Thelma and other Xarelto patients of all the drug’s side effects, because they rely on the accuracy of the given information. Timothy insists that his mother never would have taken Xarelto if she had known about the possibility of uncontrollable internal bleeding.
The Xarelto Bleeding lawsuit is Case No. 2:15-cv-00120-EEF-MBN, in the U.S District of Eastern Pennsylvania.
Overview of Xarelto Complications
Xarelto was released into the American market in 2011 as a new generation anticoagulants.
Like its predecessor Pradaxa, Xarelto is often prescribed to atrial fibrillation patients or other patients who are at high risk for stroke. Additionally, Xarelto and Pradaxa share another benefit that makes them different from the original blood-thinner, Warfarin, which is that they do not require frequent blood monitoring or dose adjustments. This makes Xarelto a more hassle-free choice compared to Warfarin, which requires just the opposite.
However, medical experts state that Warfarin is ultimately safer than the new generation anticoagulants because of its demanding blood monitoring. Warfarin also has a reversal agent in the case of bleeding injuries, which Xarelto and the other new anticoagulants lack. Despite this, Xarelto’s main marketing tactics was that it did not require constant medical observations, even though the patients could be potentially at risk. Medical experts state that if Xarelto and Pradaxa had the same check-up requirements as Warfarin, then many bleeding injuries would have been prevented.
Janssen and Bayer released Xarelto has a joint project, and have been ultimately successful due to aggressive advertising; Xarelto actually surpassed Pradaxa in popularity. However, the companies have been accused of deliberately concealing this risk of bleeding injuries from the public, in order to insure the marketing success of Xarelto. As of now, hundreds of patient across the country are suing these pharmaceutical giants for failing to protect them against Xarelto bleeding complications.
-
Xarelto bleeding lawsuits on the rise
Feb 23, 2015 | Hissey Kientz LLP
Xarelto bleeding lawsuits are on the rise as more patients come forward with complaints of side effects after using the blood-thinning drug. A West Virginia woman who suffered a gastrointestinal bleed after being prescribed Xarelto to treat atrial fibrillation is the most recent patient to file a Xarelto lawsuit.
Nova Rose alleges that Xarelto co-producers Bayer and Janssen Pharmaceuticals knew of the increased risks of bleeding associated with Xarelto, but failed to adequately warn doctors and patients. Rose’s Xarelto lawsuit also notes that there is no “antidote” for Xarelto, rendering the drug even more dangerous if a patient experiences Xarelto side effects.
Xarelto was approved to reduce the risk of blood clots in stroke patients and patients with atrial fibrillation in 2011, but many patients have since complained that the anticoagulant led to severe complications. Nearly 2,000 adverse events have been linked to the drug, including pulmonary embolism, uncontrolled bleeding, internal hemorrhaging and deep vein thrombosis.
-
Feb 20, 2015 | Oliver Law Group PC
The Xarelto attorneys at The Oliver Law Group P.C. report that all Xarelto bleeding lawsuits filed in Pennsylvania have been consolidated in the Philadelphia Court of Common Pleas. Common Pleas Administrative Judge Kevin Dougherty issued an order on January 20 2015 to create a mass tort litigation for the Xarelto complaints filed against Bayer Healthcare Pharmaceuticals, which manufacturers Xarelto, and Johnson & Johnson’s subsidiary, Janssen Pharmaceuticals, which markets Xarelto. In consolidating the Xarelto lawsuits, Judge Dougherty granted a petition from plaintiffs in Xarelto cases who asked for the consolidation due to the lawsuits having common allegations that Xarelto can cause severe and uncontrollable bleeding that can sometimes be fatal. Court records show Judge Dougherty transferred about 75 Xarelto cases to the court’s Complex Litigation Center. Since the program was created, the court’s case list shows the number of Xarelto lawsuit filings have risen to 111 as of February 18. The Xarelto claims allege that plaintiffs who were prescribed the blood thinner suffered side-effects including uncontrollable or fatal bleeding and the defendants failed to warn that the blood thinner lacks an antidote to reverse the effects of the medication. (In Re: Xarelto Litigation, Case Number 150102349)
The Oliver Law Group P.C. is offering free Xarelto lawsuit evaluations to individuals who allegedly suffered serious internal bleeding and other complications due to their use of the Xarelto blood thinner. Free legal evaluations are also being offered to families of patients who allegedly died as a result of Xarelto bleeding. To learn more about filing a Xarelto lawsuit, please contact our office by calling 800-939-7878 today.
Xarelto (rivaroxaban) is an oral anticoagulant used to treat blood clots in the leg (deep vein thrombosis) and lungs (pulmonary embolism) and to reduce the risk of stroke and blood clots in patients with atrial fibrillation (irregular hearty rhythms). Xarelto has been marketed as a more convenient blood thinner alternative than warfarin (Coumandin, Jantoven) because Xarelto does not require regular blood tests and regular dosing adjustments as does warfarin. The U.S. Food and Drug Administration (FDA) considers Xarelto, Pradaxa and Eliquis as next generation blood thinners compared to warfarin which has been on the U.S. market for 60 years. However, the older blood thinner, warfarin, uses vitamin K as an antidote for severe bleeding but the newer blood thinners do not have antidotes to reverse the effects of the anticoagulants should significant bleeding occur in patients who take the medication.
The consolidation of Xarelto lawsuits in Pennsylvania comes one month after Xarelto lawsuits filed in federal courts nationwide were consolidated in the U.S. District Court, Eastern District of Louisiana. The U.S. Judicial Panel on Multidistrict Litigation (JPML) consolidated the Xarelto complaints in December as a way to prevent inconsistent rulings and eliminate duplicate discovery as the Xarelto complaints go through the pretrial process. Recently, U.S. District Judge Eldon E. Fallon, who is assigned to manage the federal litigation, appointed 12 attorneys to a plaintiffs’ steering committee. The attorneys will represent all the plaintiffs at hearings, conduct discovery, and negotiate potential stipulations or settlement agreements with the defendants, among other things. There are 220 Xarelto lawsuits pending in the federal litigation as of February 17, that number is up from 86 Xarelto complaints in January. (In re: Xarelto (Rivaroxaban) Products Liability Litigation, MDL 2592)Court documents indicate that another Xarelto lawsuit was filed recently in the federal litigation in Louisiana that accuses Bayer Healthcare and Janssen Pharmaceuticals of failing to warn the medical community and patients that Xarelto lacked an antidote to reverse severe bleeding. The wrongful death complaint was filed on behalf of a 75-year-old Louisiana man who was prescribed Xarelto and developed severe gastrointestinal bleeding. According to the lawsuit, the man died on January 12, 2014, as a result of the Xarelto bleeding side-effect. The Xarelto complaint contended that the blood thinner’s original safety label did not include a warning regarding the lack of an antidote, “but instead only mentioned this important fact in the overdosage section.” (Case No. 2:15-cv-00041, U.S. District Court of the Eastern District of Louisiana)About The Oliver Law Group P.C. And Filing A Xarelto Lawsuit
The Oliver Law Group P.C. is a different kind of law firm. One that focuses on the needs of the injured first. A compassionate law firm dedicated to fighting for the rights of victims and their families, and doing everything necessary to ensure those rights.
Client Attorney Privileged/Attorney Work Product/At Request of Counsel
Plaintiff Attorney Press Releases
Plaintiff Attorney Blogs
Full Text of Stories Below
Add recipients
Suggested